Carregant...
Miniatura

Tipus de document

Tesi

Versió

Versió publicada

Data de publicació

Llicència de publicació

cc-by-nc-sa, (c) Suelves, 2018
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/126327

Evaluation of therapeutic targets for the treatment of behavioral alterations and neuropathology in Huntington’s disease. The role of histone deacetylase 3 and p75 neurotrophin receptor

Títol de la revista

ISSN de la revista

Títol del volum

Resum

[eng] Huntington’s disease (HD) is a rare genetic disorder caused by an aberrant expansion of a CAG trinucleotide in the huntingtin gene (Htt). The neuropathology of the disease is characterized by progressive neuronal dysfunction and degeneration in specific regions within the central nervous system, which causes a triad of symptoms including motor, cognitive and psychiatric features. Current treatments only alleviate some of these symptoms without preventing the inevitable neuropathological progression and, therefore, there is great need for finding new therapies that act at the root of the illness. Transcriptional dysregulation, somatic CAG repeat instability and neurotrophic signaling alterations appear early in HD and have been considered important underlying pathogenic mechanisms. Additionally, it has been recently suggested that HDAC3 and p75NTR could participate in some of these processes. Accordingly, the main aim of this thesis was to evaluate the potential therapeutic benefits of the pharmacological inhibition of HDAC3 and the genetic reduction of p75NTR in a knock-in mouse model of HD, termed HdhQ7/Q111. Our results have demonstrated that the selective inhibition of HDAC3 ameliorates cognitive deficits (motor learning and long-term memory alterations) in HdhQ7/Q111 mice by restoring the neuronal activity- dependent transcription of important memory-related genes, such as Arc and Nr4a2. This effect could be due to an increase in histone acetylation, leading to a relaxed DNA configuration, as well as an increase in CBP acetylation, potentially promoting its transcriptional activity. Besides, we have observed that chronic HDAC3 inhibition suppresses somatic CAG repeat expansions in Htt gene. Results of this thesis have shown that HDAC3 inhibition increases Msh2 acetylation at lysine 73, probably altering its DNA repair activity, which has been involved in promoting somatic CAG repeat length increases. Finally, our results have shown that p75NTR levels are increased in HdhQ7/Q111 mice from symptomatic stages. Interestingly, p75NTR normalization delays the onset of motor coordination alterations, several neuropathological HD hallmarks and the overall neurotrophic signaling imbalance in HdhQ7/Q111 mice, which comprise a reduction of the neurotrophin BDNF, a reduction and disrupted activation of its specific receptor, TrkB, and an overactivation of the p75NTR-dependent JNK signaling pathway. However, normalization of p75NTR levels at late disease stages is not able to prevent the loss of striatal integrity and motor coordination in KI mice. This might be the result of the unstoppable advance of other pathological mechanisms that do not depend on p75NTR expression. Therefore, a pharmacological strategy aimed to reduce the expression or activity of p75NTR in HD could provide some benefits at early stages of the disease but, as the pathogenic process progresses, the benefits would be limited. Collectively, our results have provided further insight into the contribution of transcriptional dysregulation, somatic CAG instability and neurotrophin signaling disturbances to HD neuropathological progression and highlight HDAC3 and p75NTR as promising therapeutic targets to correct these pathogenic mechanisms and ameliorate cognitive and motor behavioral impairments in HD.

Descripció

Citació

Citació

SUELVES CABALLOL, Núria. Evaluation of therapeutic targets for the treatment of behavioral alterations and neuropathology in Huntington’s disease. The role of histone deacetylase 3 and p75 neurotrophin receptor. [consulta: 8 de desembre de 2025]. [Disponible a: https://hdl.handle.net/2445/126327]

Exportar metadades

JSON - METS

Compartir registre